AU2005314617B2 - RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof - Google Patents

RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof Download PDF

Info

Publication number
AU2005314617B2
AU2005314617B2 AU2005314617A AU2005314617A AU2005314617B2 AU 2005314617 B2 AU2005314617 B2 AU 2005314617B2 AU 2005314617 A AU2005314617 A AU 2005314617A AU 2005314617 A AU2005314617 A AU 2005314617A AU 2005314617 B2 AU2005314617 B2 AU 2005314617B2
Authority
AU
Australia
Prior art keywords
rsv
sirna
agent
irna agent
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005314617A
Other languages
English (en)
Other versions
AU2005314617A1 (en
Inventor
Sailen Barik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Alabama
Original Assignee
University of South Alabama
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Alabama filed Critical University of South Alabama
Publication of AU2005314617A1 publication Critical patent/AU2005314617A1/en
Application granted granted Critical
Publication of AU2005314617B2 publication Critical patent/AU2005314617B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2005314617A 2004-10-22 2005-10-21 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof Ceased AU2005314617B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US62155204P 2004-10-22 2004-10-22
US60/621,552 2004-10-22
US11/151,893 2005-06-14
US11/151,976 2005-06-14
US11/151,976 US20060089324A1 (en) 2004-10-22 2005-06-14 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US11/151,893 US7592322B2 (en) 2004-10-22 2005-06-14 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
PCT/US2005/038269 WO2006062596A2 (en) 2004-10-22 2005-10-21 RNAi MODULATION OF RSV, PIV AND OTHER RESPIRATORY VIRUSES AND USES THEREOF

Publications (2)

Publication Number Publication Date
AU2005314617A1 AU2005314617A1 (en) 2006-06-15
AU2005314617B2 true AU2005314617B2 (en) 2011-05-26

Family

ID=36578352

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005314617A Ceased AU2005314617B2 (en) 2004-10-22 2005-10-21 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof

Country Status (12)

Country Link
US (2) US20060089324A1 (https=)
EP (1) EP1806968B1 (https=)
JP (1) JP5037349B2 (https=)
KR (1) KR101193825B1 (https=)
CN (1) CN101087527B (https=)
AU (1) AU2005314617B2 (https=)
BR (1) BRPI0517286A (https=)
CA (1) CA2584309A1 (https=)
MX (1) MX2007004692A (https=)
NO (1) NO20071953L (https=)
RU (1) RU2494745C2 (https=)
WO (1) WO2006062596A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE556714T1 (de) 2002-02-01 2012-05-15 Life Technologies Corp Doppelsträngige oligonukleotide
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP1572902B1 (en) 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US8258288B2 (en) * 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US7297786B2 (en) * 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
US7790878B2 (en) * 2004-10-22 2010-09-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
CN102600480B (zh) * 2005-01-07 2015-07-22 阿尔尼拉姆医药品有限公司 RSV的RNAi调节及其治疗应用
PL2308514T3 (pl) 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
JP2010527914A (ja) * 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
WO2009055445A2 (en) * 2007-10-22 2009-04-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
NZ585784A (en) * 2007-12-13 2012-09-28 Alnylam Pharmaceuticals Inc siRNAs for the treatment and prevention of respiratory syncytial virus (RSV) infection
EP2321414B1 (en) * 2008-07-25 2018-01-10 Alnylam Pharmaceuticals, Inc. Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
EP2350277A1 (en) * 2008-10-23 2011-08-03 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
US9494571B2 (en) 2010-03-08 2016-11-15 Novartis Ag Methods of testing for intracellular pathogens
CA2828544A1 (en) * 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
CN103703141B (zh) 2011-04-08 2016-08-17 伯乐实验室公司 具有降低的非特异性活性的pcr反应混合物
US11163898B2 (en) * 2013-09-11 2021-11-02 Mimecast Services Ltd. Sharing artifacts in permission-protected archives
JP7242180B2 (ja) 2014-09-07 2023-03-20 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物
WO2016049492A1 (en) 2014-09-26 2016-03-31 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Virus-based expression vectors and uses thereof
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
CN114206396A (zh) 2019-05-28 2022-03-18 西莱克塔生物科技公司 用于减弱抗病毒转移载体免疫应答的方法和组合物
KR20230022150A (ko) * 2020-03-13 2023-02-14 누오-베타 파마슈티컬 테크놀로지 (상하이) 씨오., 엘티디. Pi4k 억제제의 항-코로나바이러스 효과 및 적용
EP4162050A1 (en) * 2020-06-09 2023-04-12 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
EP4527927A1 (en) * 2023-09-22 2025-03-26 Medizinische Hochschule Hannover Oligonucleotide-based strategies to combat respiratory viruses
WO2026063375A1 (ja) * 2024-09-20 2026-03-26 東亞合成株式会社 Ｒｓｖ ｐタンパク質 ｒｎａ配列に基づく新規二本鎖ｒｎａ及びその利用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US20030203356A1 (en) * 2002-01-22 2003-10-30 The Cleveland Clinic Foundation RNase L activator-antisense complexes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5693532A (en) 1994-11-04 1997-12-02 Ribozyme Pharmaceuticals, Inc. Respiratory syncytial virus ribozymes
AU6848396A (en) * 1995-10-17 1997-05-07 Hybridon, Inc. Oligonucleotides with anti-respiratory syncytial virus activity
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
CA2429814C (en) * 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
WO2003008628A2 (en) * 2001-07-20 2003-01-30 Ribozyme Pharmacuticals, Inc. Enzymatic nucleic acid peptide conjugates
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
AU2003299531A1 (en) * 2002-08-05 2004-06-07 University Of Massachusetts Compounds for modulating rna interference
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US20050008617A1 (en) * 2002-09-28 2005-01-13 Massachusetts Institute Of Technology Compositions and methods for delivery of short interfering RNA and short hairpin RNA
NZ540779A (en) * 2002-11-01 2008-05-30 Univ Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
JP2007524349A (ja) * 2003-01-16 2007-08-30 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア ＩＣＡＭ−１のｓｉＲＮＡ阻害のための組成物及び方法
WO2004064737A2 (en) 2003-01-17 2004-08-05 Alnylam Pharmaceuticals Therapeutics compositions
CA2518475C (en) 2003-03-07 2014-12-23 Alnylam Pharmaceuticals, Inc. Irna agents comprising asymmetrical modifications
ES2702942T3 (es) 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
JP4991288B2 (ja) 2003-04-17 2012-08-01 アルナイラム ファーマシューティカルズ， インコーポレイテッド 二本鎖ｉＲＮＡ剤、および二本鎖ｉＲＮＡ剤の対合の安定性を調節する方法。
CA2548150A1 (en) * 2003-12-04 2005-06-23 University Of South Florida Polynucleotides for reducing respiratory syncytial virus gene expression
US7297786B2 (en) 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
CN102600480B (zh) * 2005-01-07 2015-07-22 阿尔尼拉姆医药品有限公司 RSV的RNAi调节及其治疗应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US20030203356A1 (en) * 2002-01-22 2003-10-30 The Cleveland Clinic Foundation RNase L activator-antisense complexes

Also Published As

Publication number Publication date
WO2006062596A2 (en) 2006-06-15
JP2008517940A (ja) 2008-05-29
MX2007004692A (es) 2007-09-07
US20060089324A1 (en) 2006-04-27
EP1806968B1 (en) 2012-12-05
BRPI0517286A (pt) 2008-10-07
KR20070106686A (ko) 2007-11-05
US7592322B2 (en) 2009-09-22
NO20071953L (no) 2007-05-18
RU2010139908A (ru) 2012-04-10
AU2005314617A1 (en) 2006-06-15
KR101193825B1 (ko) 2012-10-23
HK1114308A1 (en) 2008-10-31
US20060089323A1 (en) 2006-04-27
EP1806968A4 (en) 2010-06-02
CN101087527A (zh) 2007-12-12
RU2494745C2 (ru) 2013-10-10
JP5037349B2 (ja) 2012-09-26
CN101087527B (zh) 2012-01-18
WO2006062596A3 (en) 2007-05-18
CA2584309A1 (en) 2006-06-15
EP1806968A2 (en) 2007-07-18

Similar Documents

Publication Publication Date Title
AU2005314617B2 (en) RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US8598134B2 (en) RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
EP2230304B1 (en) RNAI modulation of RSV and therapeutic uses thereof
RU2409666C2 (ru) Модуляция rsv, piv и других респираторных вирусов с помощью rnai и ее применение
NZ554494A (en) RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
HK1114308B (en) Rnai modulation of rsv, piv and other respiratory viruses and uses thereof
HK1144102B (en) Rnai modulation of rsv and therapeutic uses thereof
HK1144102A1 (en) Rnai modulation of rsv and therapeutic uses thereof
HK1176083A (en) Rnai modulation of rsv and therapeutic uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired